Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
Saved in:
| Title: | Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer. |
|---|---|
| Authors: | West H; City of Hope Comprehensive Cancer Center, Duarte, CA., Hu X; Merck & Co., Inc., Rahway, NJ., Zhang S; Analysis Group, Inc., Boston, MA., Song Y; Analysis Group, Inc., Boston, MA., Chirovsky D; Merck & Co., Inc., Rahway, NJ., Gao C; Analysis Group, Inc., Boston, MA., Lerner A; Analysis Group, Inc., Boston, MA., Jiang A; Analysis Group, Inc., Boston, MA., Signorovitch J; Analysis Group, Inc., Boston, MA., Samkari A; Merck & Co., Inc., Rahway, NJ. |
| Source: | Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2023 Jul; Vol. 29 (7), pp. 749-757. |
| Publication Type: | Observational Study; Journal Article |
| Journal Info: | Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2376-1032 |
|---|---|
| DOI: | 10.18553/jmcp.2023.29.7.749 |
